Prediction and prevention of cardiovascular risk of obesity, personalized obesity treatment

Czech version

Authors: Š. Svačina
Authors‘ workplace: III. interní klinika 1. LF UK a VFN, Praha
Published in: Kardiol Rev Int Med 2011, 13(2): 77-79

Overview

Obesity carries a significant cardiovascular risk, in particular as obesity-related complications. This risk can be detected by means of metabolic syndrome components. Physical activity and diabetes prevention are the major elements that can help reduce cardiovascular risk. Personalized medicine in obesity treatment has been based on clinical factors only and the detection of risk genes has not been of any major importance yet.

Keywords:
cardiovascular risk of obesity –⁠ diabetes prevention –⁠ physical activity –⁠ diabetes treatment –⁠ metabolic syndrome

Sources

1. Byrne CD, Wild SH (eds). The metabolic syndrome. Chichester: John Wiley 2007.

2. Fantuzzi C, Mazzone T (eds). Adipose Tissue and Adipokinines in Health and Disease. 1st ed. Totowa: Humana Press 2007.

3. Jee SH, Sull JW, Park J et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355 : 779–787.

4. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355 : 763–778.

5. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999; 69: 373–380.

6. Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton 2008.

7. Šmahelová A. Konzervativní léčba diabetické mikroangiopatie a makroangiopatie. Čas Lék Čes 2009; 148: 72–77.

8. Skyler JS, Bergenstal R, Bonow RO et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53 : 298–304.

9. Kelly TN, Bazzano LA, Fonseca VA et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394–403.

10. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 : 1577–1589.

11. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá Fronta 2010.

12. Fried M a kol. Bariatrická a metabolická chirurgie. 1. vyd. Praha: Mladá Fronta 2011.

13. Svačina Š a kol. Poruchy metabolismu a výživy. 1. vyd. Praha: Galén 2010.